{"id":"W3214073113","doi":"10.1182/blood-2021-147293","title":"OMNIVERSE: A Phase 1b/2 Study of Oral Azacitidine Plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed (ND) Acute Myeloid Leukemia (AML)","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Venetoclax; Azacitidine; Medicine; Refractory (planetary science); Myeloid leukemia; Internal medicine; Leukemia; Oncology; Myeloid; Phases of clinical research; Gastroenterology; Clinical trial; Biology","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001447381,0.001166484,0.001766823,0.0003438183,0.0003466425,0.001079728,0.0007944521,0.0009638017,0.005592186],"category_scores_gemma":[0.0006455145,0.0004880029,0.001111183,0.0003015809,0.0008073531,0.0008057043,0.0003879823,0.003073864,0.0009969458],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000652379,"about_ca_system_score_gemma":0.001220937,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00136087,"about_ca_topic_score_gemma":0.00377773,"domain_scores_codex":[0.999774,0.0001033614,0.00001145708,0.0000430672,0.0000208923,0.00004719927],"domain_scores_gemma":[0.9996062,0.000062922,0.00005607196,0.00003066717,0.00002578472,0.0002183792],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7659885,0.08727854,0.004911352,0.001590095,0.001681062,0.0002612832,0.0003184308,0.001547648,0.03174698,0.0003862238,0.004208605,0.1000812],"study_design_scores_gemma":[0.6721799,0.3125518,0.008357048,0.00005372159,0.0006603345,0.000179054,0.00007409252,0.0006376163,0.001754883,0.0001492648,0.003373411,0.00002881793],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9877414,0.003503657,0.000460536,0.0005960907,0.0002085736,0.002776585,0.001864326,0.0001296426,0.002719226],"genre_scores_gemma":[0.9793358,0.004304184,0.002227483,0.001182971,0.0002798918,0.002899477,0.004017185,0.00004782743,0.005705309],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005592186,"threshold_uncertainty_score":0.01870775,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01874568387630128,"score_gpt":0.2908580006501083,"score_spread":0.272112316773807,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}